Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: Real-world Multicenter Observational Study
TCTR20260314001Completed
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Aug 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Primary endpoints: Efficacy outcomes and Safety outcomes. Started Aug 2023; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20260314001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260314001.